Gland Pharma Ltd. · NSE:GLAND
Gland Pharma — Q3 FY23 Earnings Presentation
12 slides from Gland Pharma's earnings presentation, Jan 23, 2023
Slide 1: Gland Pharma Limited Financial Results Q3 FY23
Gland Pharma Limited Financial Results Q3’FY23 23rd January 2023
Slide 2: Safe Harbor Statement
Safe Harbor Statement The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation
Slide 3: Financial Highlights (1/3)
Financial Highlights (1/3) Revenue from Operations EBITDA (1) / EBITDA Margin (2) (INR Mn) (INR Mn / %) - 12% 13,205 10,633 32,977 10,579 9,383 28,396 3,946 3,511 36% 37% 35% 38% 35% Q3 FY22 Q3 FY23 9M FY22 9M FY23 Q3 FY22 Q3 FY23 9M FY22 9M FY23 PBT / PAT / PAT Margin (3) R&D Expenses / (R&D % of R
Slide 4: Financial Highlights (2/3)
Financial Highlights (2/3) Net Worth (1) Cash and Bank Balances / Net Cash (2) (INR Mn) (INR Mn) 78,841 71,576 38,297 38,259 34,483 34,444 Mar'22 Dec'22 Mar'22 Dec'22 Networth Total Cash Net Cash Net Working Capital (3) Capital Expenditure (INR Mn) (INR Mn) 23,322 4,547 20,217 1,253 Mar'22 Dec'22 9M
Slide 5: Financial Highlights (3/3)
Financial Highlights (3/3) Asset Turnover Ratio (1)(2) ROCE (ex-cash)(3) / ROCE (4) / RONW (5) (%) 3.2 2.8 34% 33% 2.4 19% 20% 18% 12% 0.7 0.7 19% 19% 0.5 12% Total asset turnover Fixed asset turnover 9M FY22 FY22 9M FY23 9M FY22 FY22 9M FY23 RoCE (Ex-Cash) RoCE RoNW Cash Flow from Operations Cash C
Slide 6: Operational highlights
Operational highlights Factors impacting revenue growth in 9M-FY23: • Headwinds in the US business with reduced off-take of products • Supply chain disruption resulting in production delays • Impact due to inventory at customers end for certain products • Normalization of COVID related sales Key upd
Slide 7: P&L Highlights
P&L Highlights (INR Mn) YoY YoY Particulars Q3 FY23 Q3 FY22 9M FY23 9M FY22 Q2 FY23 change change Revenue from operations 9,383 10,633 -12% 28,396 32,977 -14% 10,444 Other Income 615 457 35% 2,015 1,587 27% 656 Total Income 9,998 11,090 -10% 30,411 34,564 -12% 11,100 Gross Margin(1) 5,112 5,599 -9%
Slide 8: USA, Europe, Canada, Australia and New Zealand (Core Markets)
USA, Europe, Canada, Australia and New Zealand (Core Markets) ▪ Revenue: 9M FY23: Rs. 21,158 Mn Q3 FY23: Rs. 6,626 Mn YoY Change: -4% YoY Change: -11% The performance was impacted by supply chain issues along with production delays. Impact was also seen due to inventory at customers end for certain
Slide 9: Rest of the World Markets
Rest of the World Markets ▪ We saw a de-growth of 4% over the last year, the 9M FY23: Rs. 5,188 Mn Q3 FY23: Rs. 1,943 Mn contribution of rest of the world markets to over-all YoY Change: -21% YoY Change: -4% revenue remains at 21% Rest of the World Markets ▪ Our key products in the rest of the world
Slide 10: India (Domestic Market)
India (Domestic Market) 9M FY23: Rs. 2,050 Mn Q3 FY23: Rs. 814 Mn ▪ India market sales accounted for 9% of our total sales YoY Change: -52% YoY Change: -32% during Q3 FY23. ▪ Post line improvements on our Insulin line, we are in the India (Domestic Market) process of ramping-up production ▪ We are l
Slide 11: Growth Drivers
Growth Drivers 1 ▪ China remains a key geographic focus, we are in advanced stages of regulatory review for a couple of products Geographic filed in China, and expect approvals very soon Expansion ▪ We are expanding our penetration in the rest of the world markets such as South Africa and Kazakhstan
Slide 12: GLAND
Registered Office Corporate Office: Gland Pharma Limited Gland Pharma Limited Survey No. 143-148, 150 & 151 Plot No. 11 & 84, TSIIC Phase: IV Near Gandimaisamma 'X' Roads Pashamylaram (V), Patancheru (M), D.P. Pally, Dundigal Gandimaisamma Mandal Sangareddy District Medchal-Malkajgiri District Hyder